Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02264873 · ClinicalTrials.gov registry record · Phase 1
Phase I, Dose Escalation Study of Decitabine
A Phase 1 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02264873 is a Phase 1 study that has completed, run by University of Florida. The registered enrollment target is 3 participants.
The verdict
NCT02264873, a Phase 1 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML). This study is based on the hypothesis that Decitabine delivered after allo-hematopoietic stem cell transplant (HSCT) in patients with leukemia will enhance disease control by the allogeneic immune system and lead to a longer disease free survival. The study is designed to provide safety data of low-dosing in the post-transplant setting.
Interventions
- DRUG Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02264873
The ClinicalTrials.gov registry entry for NCT02264873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine is the first listed.
NCT02264873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02264873 about?
NCT02264873 is a clinical study titled "Phase I, Dose Escalation Study of Decitabine". Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML). This study is based on the hypothesis that Decitabine delivered after allo-hematopoietic stem cell transplant (HSCT) in patients with leukemi...
What is the current status of trial NCT02264873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-10. Estimated completion is 2018-09-18.
What interventions are being tested in trial NCT02264873?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT02264873?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.